Identification of Dihydroceramide Desaturase as a Direct in Vitro Target for Fenretinide
Open Access
- 1 July 2011
- journal article
- Published by Elsevier BV
- Vol. 286 (28), 24754-24764
- https://doi.org/10.1074/jbc.m111.250779
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Dihydroceramide desaturase activity is modulated by oxidative stressBiochemical Journal, 2010
- Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomasBritish Journal of Cancer, 2009
- N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killingMolecular Cancer Therapeutics, 2008
- Principles of bioactive lipid signalling: lessons from sphingolipidsNature Reviews Molecular Cell Biology, 2008
- Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinideCancer Chemotherapy and Pharmacology, 2007
- Involvement of Dihydroceramide Desaturase in Cell Cycle Progression in Human Neuroblastoma CellsPublished by Elsevier BV ,2007
- Synthetic retinoid fenretinide in breast cancer chemopreventionExpert Review of Anticancer Therapy, 2007
- Dihydroceramide hinders ceramide channel formation: Implications on apoptosisApoptosis, 2006
- Biologically active sphingolipids in cancer pathogenesis and treatmentNature Reviews Cancer, 2004
- Chemoprevention of Breast Cancer with FenretinideDrugs, 2001